Dr David Woolf is a Consultant Clinical Oncologist based at The Christie NHS Foundation Trust in Manchester.
Dr Woolf is a graduate of the University of Birmingham. Core medical and Clinical Oncology training was carried out in London (University College Hospital, The Royal Free and St Bartholomew’s), a Master’s Degree in Oncology at the Institute of Cancer Research and a Doctorate of Medicine after research at Mount Vernon Cancer Centre.
Dr Woolf plans and delivers radiotherapy at The Christie to patients with breast and lung cancers and also gives Stereotactic Ablative Radiotherapy (SABR) for lung cancers and oligometastases (cancers that have spread to the lungs). In addition he gives chemotherapy, endocrine therapy (hormone treatment) and targeted drug therapy.
He is a member of the breast and lung cancer disease orientated group at The Christie and remains up to date with the rapid ongoing changes in cancer treatment.
Dr Thomas Newsom-Davis is a Consultant Medical Oncologist based at The Chelsea and Westminster Hospital NHS Foundation Trust.
Dr Newsom-Davis trained at University College and Middlesex School of Medicine, and graduated in anatomy and medicine in 1998. He subsequently specialised in medical oncology at Charing Cross and Hammersmith Hospitals. During this time he completed a PhD in tumour immunology, funded by Cancer Research UK, and went on to become a Clinical Lecturer in medical oncology at Imperial College London, supported by the Wellcome Trust and Academy of Medical Sciences. He has published several peer-reviewed papers and presented at many conferences.
Dr Newsom-Davis specialises in the treatment of lung cancer, mesothelioma and other thoracic malignancies. Dr Newsom-Davis has taught widely at both under-gradate and post-graduate levels, as well as being an invited lecturer for various organisations including the Royal College of Physicians and the British Medical Journal. He foundered the first Royal Society of Medicine/LCA acute oncology course, and also runs regular simulation based acute oncology training courses at Chelsea and Westminster. His work was recognised in the 2011 Health Services Journal Awards.
Awards Dr Newsom-Davis has received include: 2011 Health Services Journal Awards, Clinical Service Redesign (short listed), 2006 McElwain Scholarship, Association of Cancer Physicians, and in 2006 President’s Prize, Royal College of Physicians.
He is a member of the Royal College of Physicians, Association of Cancer Physicians, European Society of Medical Oncology, British Thoracic Oncology Group and the British Medical Association.
Professor SM Lee is a Professor of Medical Oncology at UCL Cancer Institute and Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and a Consultant Oncologist at UCLH.
Prof Lee studied medicine at St Mary’s Hospital Medical School, University of London, before completing his medical oncology fellowship training at Guy’s and Christie Hospitals. He was a recipient of the American Association for Cancer Research Upjohn Award in 1993, McElwain Prize by the Association of Cancer Physicians in 1994, and completed his postgraduate PhD degree at CRUK Manchester Paterson Institute in 1994. He was appointed a Consultant Medical Oncologist at UCLH in 1998 to specialize in the treatment lung cancer and lymphoma.
Professor Justin Stebbing is a Consultant Medical Oncologist based at Imperial College Healthcare NHS Trust in London.
Professor Stebbing trained in medicine at Trinity College Oxford, where he gained a triple first class degree. After completion of junior doctor posts in Oxford, he undertook a residency at The Johns Hopkins Hospital in the US, returning to London to continue his training in oncology at The Royal Marsden and St Bartholomew’s Hospitals. Professor Stebbing’s PhD research investigated the interplay between the immune system and cancer.
Professor Stebbing has published over 500 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing for national newspapers and presenting new data on optimal cancer therapies at major international conferences. His focus is on new therapies in cancer, and the systemic management of patients with a variety of solid malignancies, including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells. His laboratory work is concentrated on new druggable target discovery.
He is a member of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of five biotechnology companies. He chairs the World Vaccine Congress and is on the editorial board of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology and Oncogene and writes BMA guidelines for several cancers.
Dr Dawn Carnell is a Consultant Clinical Oncologist based at University College Hospital, London.
Dr Carnell is the clinical lead consultant clinical oncologist for lung cancer at UCH, and the lead consultant clinical oncologist in head and neck cancer. Her research (MD), sponsored by Cancer Research UK, and based at The Mount Vernon Cancer Centre, looked at hypoxia (low oxygen levels) in cancer and how this could be mapped histologically and using Blood Oxygen Level Dependent Magnetic Resonance Imaging. The future role for this would be to direct radiation boosts to radio-resistant hypoxic regions in cancer and to identify hypoxic tumours for specific treatments aimed at hypoxic cancer cells, translating to improved cure rates.
Dr Carnell also enjoys teaching and is one of the Lead Clinicians for Medical Student Teaching (the Head and Neck/Lung and CNS group) and contributes regularly to registrar teaching within oncology and ENT.
Dr David Landau is a Consultant Clinical Oncologist at Guys and St. Thomas' NHS Trust.
Dr Landau qualified at Charing Cross and Westminster Medical School (now part of Imperial) in 1990. Most of his training in Clinical Oncology was at Charing Cross Hospital and he finished his training with clinical and research posts at The Royal Marsden Hospital.
Dr Landau now specialises only in cancers of the thorax, lung cancers, mesothelioma and thymoma. He also has a specialist interest in metastatic disease from many primaries. He has a particular interest in high-tech radiotherapy treatments.
Dr Landau is one of one founders of London Oncology Clinic in Harley Street and speaks English and French.
Professor Chris Nutting is a Professor of Clinical Oncology based at The Royal Marsden Hospital, London.
Prof Nutting is a world leading Oncologist. Operating from his Central and West London practices, he specialises in the management of cancer of the head and head, thyroid, thorax and other forms. He is an expert in solid cancer treatment with state of the art radiotherapy techniques such as conformal and intensity modulated radiotherapy designed to reduce complications of treatment and improve cure rates.
In June 2001 Professor Nutting was appointed Consultant and Senior Lecturer in Clinical Oncology at the Royal Marsden Hospital, where his clinical responsibilities and special interests include the management of patients with head and neck and lung cancers. He is the Clinical Director of the Head and Neck Unit at the Royal Marsden Hospital in London.
He has an extensive clinical practice in head, neck and lung cancer and participates in Nation Research protocols. He is regularly asked to speak at National and International clinical meetings on head and neck and lung tumours.
Professor Tim Eisen is a Medical Oncologist and clinical trialist based at Addenbrooke's Hospital and Cambridge University.
Professor Eisen is interested in developing new treatments for advanced disease, identifying and managing those at risk of disease. His special clinical areas are kidney cancer, lung cancer and melanoma. In kidney cancer and melanoma he has been particularly involved in the development of tyrosine kinase inhibitors as therapeutic agents.
Professor Eisen is a Fellow of the Royal College of Physicians; American Society for Clinical Oncology; European Society for Medical Oncology, a Trustee of Macmillan, a Member & Trustee of Kidney Cancer UK and Medical Advisor to Kidney Cancer Association.
Dr Paula Wells is a Consultant Clinical Oncologist based at Barts NHS Trust.
Dr Wells' oncology training was undertaken at St. Bartholomew’s, UCLH and Mount Vernon Hospitals. Following her Fellowship, she undertook a postgraduate research degree at Imperial College School of Medicine, Hammersmith Hospital. There she investigated the potential for Positron Emission Tomography (PET) to demonstrate the biological effects of chemotherapy in tissue. She has published a number of papers in this area and was awarded a PhD for her work. Subsequently she completed her post doctoral training at the Royal Marsden Hospital, principally with the Academic Urology Unit.
Dr Paula Wells specialises in the management of patients with genitourinary (bladder and prostate) and thoracic (lung and mesothelioma) malignancies. Furthermore Dr Wells has expertise in the delivery of real time dynamic prostate brachytherapy for patients with early stage, localised prostate cancer.
Dr Wells has recieved numberous awards including :
Rohan Williams Medal CLinical Oncology 1994
British Oncological Association Young Investigator Award 1996
European Society for Therapeutic Radiation Oncology Travel Award 1996
Winner of Royal College of Radiologists national competition for Glaxo Wellcome Fellowship 1996
American Society Clinical Oncology Merit Award 1997
Cancer Research Campaign Clinical Research Fellowship 2000
Dr Nick Reed is a Consultant Clinical Oncologist based at Cheltenham General Hospital.
Dr Reed qualified in Southampton and worked as a junior doctor in Winchester, Portsmouth and Cheltenham. Further experience in medicine was gained working in Belize and New Zealand.
He underwent his Oncology training on the Wessex training scheme, working in Southampton, Poole and Portsmouth. Prior to his consultant appointment, he spent one year as a research fellow in Radiation Oncology at the Peter MacCallum Cancer Institute, Melbourne where he furthered his interest in gastro-intestinal radiotherapy.
Dr Reed is a member of the Royal College of Radiologists.